MIMEDX GROUP INC (MDXG)
US6024961012 - Common Stock
Noteworthy Thursday Option Activity: RMD, MDXG, XOM
MiMedx Group Enters Oversold Territory (MDXG)
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its...
Oversold Conditions For MiMedx Group (MDXG)
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the...
MiMedx Group Non-GAAP EPS of $0.04 misses by $0.02, revenue of $87M beats by $1.85M (NASDAQ:MDXG)
MiMedx Group reports Q4 Non-GAAP EPS of $0.04, missing expectations by $0.02, while revenue of $87M exceeds estimates by $1.85M.
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million...
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management...
Get Rich Quick With These 3 Biotech Stocks to Buy Now
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities...
ROSEN, A TOP RANKED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors...
MiMedx gets FDA warning letter over Axiofill production (NASDAQ:MDXG)
MiMedx (MDXG) has received an FDA warning letter regarding production of its product Axiofill and reiterated its 2023 net sales growth forecast. Read more here.
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently...
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding...
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior...
MDXG Makes Notable Cross Below Critical Moving Average
Commit To Buy MiMedx Group At $5, Earn 9.6% Annualized Using Options
MIMEDX to Highlight Published Data at SAWC Fall
Company Will Sponsor Lunch Symposium on November 3, 2023...
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the...